NEWS

WIRES

OTHER

Celsync(TM), New Immune System-Enhancing Nutrient, Now Available

New Glyconutrient Discovery Is Based on Nobel-Prize Winning Research

Glycology, Inc. (OTC: GYLG) introduced Celsync(TM) today, a breakthrough all-natural product that enhances the immune system by improving the way cells communicate.

Available at www.celsync.com, Celsync(TM) is an all-natural glyconutrient that surrounds and coats each cell with all eight essential saccharides, a form of carbohydrate. Glyconutrients are so important to our immune systems, Nobel Prize winning research suggests, that maintaining healthy levels may help prevent a wide range of illnesses. The eight essential saccharides are instrumental in directing antibodies to the site of infections. Without proper communication between cells (signals carried by glyconutrients like those in Celsync(TM)) necessary antibodies and nutrients can be blocked from even reaching cells. Celsync's(TM) role is to boost the body's immune system, and prevent cellular transfer abnormalities, thus defending against disease. It may even heal and improve existing conditions.

About Glycology

Glycology, Inc. is a life sciences company committed to developing new beneficial technology that enhances and improves human health and performance. The company's flagship product, Celsync(TM), is an all-natural dietary supplement based on Nobel Prize winning molecular science.

Corporately, Glycology, Inc. currently has 2,800,000 shares outstanding, with a float of 360,000 shares.

For more information about Glycology, Inc go to http://www.glycology.com or Celsync(TM), go to http://www.celsync.com/

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, technical development risks, seasonality and other risk factors.

Distributed by Market Wire